TU
ALNY icon

TDAM USA’s Alnylam Pharmaceuticals ALNY Stock Holding History

TDAM USA’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,467
Closed -$258K – 391
2015
Q1 		$258K Buy
2,467
+150
+6% +$15.2K 0.01% 370
2014
Q4 		$225K Buy
+2,317
New +$215K 0.01% 299

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

TDAM USA's ALNY Position: Q2 2015 in Review

TDAM USA sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2015, closing a stake of 2,467 shares — an estimated $258K sold.

TDAM USA first reported a position in ALNY in Q4 2014 and held it in 2 quarters. The position peaked at $258K in Q1 2015. 278 funds tracked by Wall St. Rank hold ALNY as of Q2 2015.

  • TDAM USA reported no remaining Alnylam Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • TDAM USA sold 2,467 Alnylam Pharmaceuticals shares in Q2 2015, an estimated $258K.
  • TDAM USA first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • TDAM USA's Alnylam Pharmaceuticals position peaked at $258K in Q1 2015.
  • 278 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2015.

Based on TDAM USA's 13F filing for Q2 2015, filed 11 Aug 2015.